The Three A’s of Launch Readiness – Strategizing for success

Jesper Nissen

It can take years to develop a drug – a launch can fail in a matter of weeks

Getting a drug from bench to launch takes an average of 12 years and $1.5 billion.1 Given responsible guardianship and the careful promotion to be expected at that level of investment, it should come as a surprise when any drug falls flat at launch.

But it doesn’t – drug launch failures happen more frequently than pharma companies care to admit. From 2009-2017, approximately 50% of drug launches failed to meet prelaunch sales expectations. Over 25% didn’t meet half their forecasted revenues.2 Of the 0.02% of candidate drugs (I in 5000) that successfully reach the market, only a third meet first-year financial expectation.3

And when launches fail, the rationalizations begin: Bad luck. Bad timetables. Unforeseen complications. Unforeseeable competition. The messaging underwhelmed the target audiences. The drug costs overwhelmed the messaging. The drug overpromised, the drug underperformed.

Any and all of these may be true. But, when each case is scrutinized individually, the evidence usually points to one of three problems: the pharma brand managers and their teams did not anticipate their own overconfidence or the moves of their competitors, they did not adapt their strategies to new market conditions as they arose, or they did not align their strategy and implementation plans across functions and geographies.

Anticipate, Adapt and Align – the three A’s of successful launch strategy. To understand and implement them require more than sending out an email meeting request and marking off a block of squares on a Gantt chart. It takes strategic vision, a holistic understanding of every vagary of the marketplace, and a forthright and ruthlessly honest assessment of both the product being launched and the competitive space it is meant to occupy.

Deallus Three As of Launch Readiness White paper
DOWNLOAD WHITE PAPER

About the author

Jesper Nissen, Principal, at Deallus London

Jesper Nissen

Jesper is a Deallus consultant who has led a wide range of projects over his 5 year career at Deallus. He offers extensive experience in competitive landscape monitoring, manufacturing and diagnostics technology assessments, and global positioning and brand planning projects. His expertise covers several therapy areas including oncology, respiratory, rheumatology and rare diseases. More about Jesper

You may also be interested in…

Deallus Keynote at Pharma CiMi.CON EU 2019

Jonas gives a keynote speech that delves into the importance of strategic intelligence for pharma given today’s dynamic and disruptive marketplace. He explores how competitive and strategic intelligence are related, how to build more strategically focused engagements, and how to help decision makers realize the value in strategic partnerships with their intelligence teams.

  • Deallus Gene Therapy Article - Gene Therapy Through Different Lenses

Gene therapy through different lenses

After decades of clinical research and numerous setbacks, the promise of gene therapy is now much more than a glimmering hope on the horizon. Gene therapy is poised to revolutionize medicine as it presents the opportunity to remove or change the content of an individual’s genetic code in order to potentially treat or cure disease. We explore gene therapy from a few different lenses to give a full picture of where this innovation currently stands.